AzTrials
AzTrials

Morbid ObesityNCT00488930

Characteristics of Dendritic Cells Before and After Gastric Banding

An observational study of Morbid Obesity and Hyperglycemia, run by University of California, San Diego at 1 site in United States.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

A research study to find out more about a specific white blood cell called a dendritic cell. These cells are found in a layer of fat in the body called the omentum. The omentum is a layer of fat that covers the bowels (intestines) and protects them. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Morbid Obesity, Hyperglycemia, Diabetes Mellitus
What is being tested?
Observational
How many people
7 participants
Where
1 siteUnited States
Study dates
Jun 2007to Jan 2011
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: All subjects being treated for obesity at this institution

Who may be able to join

  • For gastric banding subjects to qualify for study inclusion, subjects have to have a BMI ranging from 33-40. Currently a BMI of 33 is our lower level of acceptable for bypass. Subjects with a BMI>40 will be excluded because their fat cells are very large and therefore fragile and unsuitable for research use.
  • Control Group:
  • All adult subjects 18 years or greater being seen in the minimally invasive surgery clinic for elective laparoscopic surgery will also be screened.
  • These will be subjects who are non-obese (BMI<30) and undergoing laparoscopic surgery for a different indication such as hernia repair or cholecystectomy. These will be patients who are undergoing elective procedures to minimize the impact an acute inflamed abdomen may have on the fat cells.

Who cannot join

  • Women who are pregnant or planning to become pregnant will be excluded from this study. Gastric banding cannot not be performed on pregnant women.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • UCSD Medical Center

    San Diego, California, 92103

Other trials in United States

About this study

A research study to find out more about a specific white blood cell called a dendritic cell. These cells are found in a layer of fat in the body called the omentum. The omentum is a layer of fat that covers the bowels (intestines) and protects them.

The purpose of this study is to allow us to compare dendritic cells in normal weight individuals to the dendritic cells of people who are extremely overweight. These cells will be collected from the omentum, the layer of fat that covers and protects the bowels (intestines), from the mesentery, which is another layer of fat that surrounds the intestines directly, and from the subcutaneous tissue, which is the layer of fat just under the skin.

Read the detailed description

Obesity continues to be a major source of morbidity and mortality in the United States. The association between obesity and type II diabetes is well known. Several studies suggest that fat may generate a low grade inflammatory response that may be responsible for the metabolic changes in obese patients. More specifically, a certain type of white blood cell that causes inflammation called a dendritic cell has been found in high concentrations in omental fat. This cell has not been extensively studied in human patients with morbid obesity, though it may play a central role in the development of insulin resistance. Aside from weight loss, the surgical treatment of obesity also results in a decrease in the markers of inflammation. Many of the comorbidities of morbid obesity improve or are cured. Laparoscopic adjustable gastric banding is safer than other gastric bypass procedures and results in similar amounts of weight loss after 2 years postoperatively.

Much of the work regarding dendritic cells in human subjects has been in patients with Crohn's disease. Both the cytokine profile and characteristics of the dendritic cells have been extensively studied in Crohn's patients, but not in obese individuals. In addition to this, these cells have not been re-evaluated after a period of weight loss.

A more detailed analysis of the inflammation of obesity and its subsequent resolution with weight loss will contribute to the growing body of information on this subject. Further work will lend insight into the pathogenesis of the comorbidities of obesity and may contribute to uncovering potential treatments for these illnesses. Dendritic cells have been extensively studied in animal models. We now know specific cell surface markers and signaling pathways for these cells, their responses to stimulating factors, and their ability to secrete anti-inflammatory cytokines such as IL-10. We hope to translate these findings to humans.

It is now recognized that chronic low-grade inflammation is the critical element leading to insulin resistance in insulin target cells. The evidence for this is substantial, including consistent measurements of elevated inflammatory markers in plasma from insulin resistance/diabetic humans and rodents. This concept was further established by the recent discovery that obese adipose tissue contains large numbers of resident macrophages. In fact, in the lean state, about 10% of all the cell types within adipose tissue consist of macrophages, and this number can go as high as 50% in obesity. Furthermore, FACS sorting of adipose tissue macrophages based on surface markers, has indicated that it is a subpopulation of macrophages which accounts for this remarkable increase. This subpopulation involves macrophages which are positive for F4/80, CD11B and CD11C and are, therefore, dendritic-like in their phenotype. There are also reports in the literature which suggests that visceral adipose tissue may be particularly "inflamed" compared to subcutaneous adipose tissue and that increased macrophage infiltration and inflammatory markers are expressed in visceral fat. More recent evidence, in which the macrophage inflammatory pathway is specifically disabled, in knock-out mice, conclusively demonstrates that the macrophage can be the initiating or orchestrating cell type responsible for the inflammatory response which ultimately leads to systemic insulin resistance.

These concepts will be assessed in using the subcutaneous and visceral fat samples obtained under this protocol. The adipose tissue samples will be collagenase digested to release all of the adipocytes and non-adipocyte cell types within the tissue. Using differential centrifugation and filtration, the stromal vascular fraction (SVF) will be separated from the adipocytes. The SVF contains the macrophages, and these cells will undergo FACS analysis based on the expression of F4/80, CD11B and CD11C to determine the absolute number of macrophages within a given adipose tissue sample, and the proportion of classical macrophages versus dendritic cell-like macrophages. The cells will then be sorted, and inflammatory marker expression will be measured in the classical macrophages (F4/80 positive, CD11B positive, but CD11C negative) versus the dendritic-like cells (F480 positive, CD11B positive, and CD11C positive). This analysis will involve direct measurement of cytokine expression by these cells (TNF, IL-1, and IL-6) as well as PCR-based measurements of mRNA expression of inflammatory pathway components. These measurements will be performed on the subcutaneous and visceral adipose tissue obtained at the time of the initial surgery, as well as on the subcutaneous adipose tissue samples at follow up after weight reduction.

Being tested
Observational
Keywords
Obesity, Hyperglycemia, Diabetes Mellitus Type I, Diabetes Mellitus Type II
Medical subject headings
Obesity, Morbid, Hyperglycemia, Diabetes Mellitus, Obesity, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • ObservationalOther

    data collection ONLY

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Jun 2007 (estimated)
  2. Study startJun 2007
  3. Primary completionJan 2011
  4. Study completionJan 2011

Why it stopped: Terminated due to a lack of recruitment and decision by the PI not to continue.

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Prospective
Enrolment
7 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00488930
Sponsor's protocol ID
070685
Other IDs
Internal Funding, NIH MED 1736
Status last verified
Oct 2016
First submitted
11 Jun 2007
Last updated
26 Oct 2016
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Morbid Obesity and Hyperglycemia, run by University of California, San Diego at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 26 Oct 2016. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study was stopped early (reason given: Terminated due to a lack of recruitment and decision by the PI not to continue.). Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Measure changes in dendritic cells at baseline, 6 months and 1 year following weight loss (time frame: 1 year). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Oct 2016; AzTrials last refreshed its copy on 7 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in